Shanghai Haohai Biological Technology Co Ltd Shs -H- Unitary 144A/Reg S 06826
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 42.00
- Day Range
- HKD 41.80–42.30
- 52-Week Range
- HKD 30.30–50.20
- Bid/Ask
- HKD 42.10 / HKD 42.40
- Market Cap
- HKD 7.09 Bil
- Volume/Avg
- 46,800 / 130,558
Key Statistics
- Price/Earnings (Normalized)
- 14.62
- Price/Sales
- 2.38
- Dividend Yield (Trailing)
- 1.08%
- Dividend Yield (Forward)
- 2.87%
- Total Yield
- 2.47%
Company Profile
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to single operating segment which is the manufacture and sale of biologicals, medical hyaluronate and intraocular lens, research and development of biological engineering and pharmaceutical products and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 2,158
- Website
- https://www.3healthcare.com
Comparables
Valuation
|
Metric
|
06826
|
603566
|
300573
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.62 | 49.67 | 114.35 |
Price/Book Value | 1.09 | 2.21 | 18.62 |
Price/Sales | 2.38 | 5.16 | 21.22 |
Price/Cash Flow | — | 24.89 | 94.81 |
Price/Earnings
06826
603566
300573
Financial Strength
|
Metric
|
06826
|
603566
|
300573
|
|---|---|---|---|
Quick Ratio | 4.47 | 2.52 | — |
Current Ratio | 5.43 | 3.00 | — |
Interest Coverage | 53.27 | — | — |
Quick Ratio
06826
603566
300573
Profitability
|
Metric
|
06826
|
603566
|
300573
|
|---|---|---|---|
Return on Assets (Normalized) | 6.01% | 3.63% | 13.32% |
Return on Equity (Normalized) | 7.54% | 4.33% | 15.90% |
Return on Invested Capital (Normalized) | 6.31% | 4.16% | 14.96% |
Return on Assets
06826
603566
300573
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Thbtrbchj | Blx | $572.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cfbwdkmqy | Xygzdfx | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Frvhcwbvp | Rnvnjt | $99.2 Bil | |
MRNA
| Moderna Inc | Xslbntg | Qqsk | $42.7 Bil | |
ARGX
| argenx SE ADR | Hclgtst | Dyhq | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Rqbrdgxkj | Jtzn | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xzbydwbx | Yhgdkz | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ccmlqxxhq | Znwmpf | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Skdqhfgv | Ghcjv | $12.7 Bil | |
INCY
| Incyte Corp | Mbwkcyl | Hwvrx | $11.9 Bil |